IceCure Medical Ltd (ICCM)
| Market Cap | 47.01M |
| Revenue (ttm) | 2.91M |
| Net Income (ttm) | -15.61M |
| Shares Out | 45.64M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 567,027 |
| Open | 1.05 |
| Previous Close | 1.09 |
| Day's Range | 1.01 - 1.20 |
| 52-Week Range | 0.52 - 4.73 |
| Beta | 3.28 |
| Analysts | Strong Buy |
| Price Target | 3.50 (+239.81%) |
| Earnings Date | Aug 14, 2023 |
About ICCM
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel. [Read more]
Financial Performance
In 2022, ICCM's revenue was $3.09 million, a decrease of -25.45% compared to the previous year's $4.14 million. Losses were -$16.98 million, 71.6% more than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ICCM stock is "Strong Buy." The 12-month stock price forecast is $3.5, which is an increase of 239.81% from the latest price.
News
IceCure's ProSense® Deepens Regulatory Approval in India
ProSense® is already marketed and sold in India based on previous regulatory requirements and now has been re-classified due to new regulations Breast cancer cryoablation is already performed in India...
IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate
Independent study concluded: - IceCure system offers significant advantage in ability to re-treat tumors that are initially resistant, achieving a subsequent local control rate of 100% - 92.4% of pati...
IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights
ProSense® system and disposables sales continue upward trend compared to the equivalent prior year period Expanded regulatory footprint, growing body of evidenced-based data, and distribution agreemen...
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer
Objective is to reopen file to address comments and find appropriate comparator group that is more representative of the patient population the Company is seeking to treat with its ProSense® system Co...
IceCure Medical to Report Third Quarter 2023 Financial & Operational Results on November 15, 2023
CAESAREA, Israel , Nov. 8, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablatio...
Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's ProSense® Cryoablation System
Independent, non-sponsored studies by doctors using ProSense® to treat cancers of the breast, lung, kidney, and musculoskeletal system, as well as endometriosis and fibroadenomas Growing body of scien...
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
CAESAREA, Israel , Nov. 3, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), a developer of the ProSense® System, a minimally-invasive cryoablation technology that...
IceCure's ICE3 Trial Results Demonstrating 96.91% Recurrence Free Rate Featured in a Presentation at BISICON 2023 in India
ICE3 trial will be finalized in Q1 2024 IceCure's distributor in India, Novomed, exhibited ProSense® and received a high level of interest from doctors, clinics, and hospitals ProSense was used to per...
Independent Scientific Paper by Doctors Using IceCure's ProSense® Published in Journal of Breast Imaging Presents Advantages of Cryoablation Breast Conserving Over Surgery in Early Breast Cancer Patients
Paper cites IceCure's ICE3 interim clinical study results as evidence of safety and efficacy of cryoablation in early-stage breast cancer CAESAREA, Israel , Oct. 25, 2023 /PRNewswire/ -- IceCure Medi...
Women Deemed Inoperable for Breast Cancer Benefitted from IceCure Medical's ProSense as an Independent Study Performed in Italy Showed a Tumor Reduction Rate of 93.43% to 96.81%
Disappearance of lesions and absence of residual malignant cells in Luminal-A group considered to be predictive for the complete effectiveness of the treatment This is the latest in a growing body of ...
Independent Study Validates IceCure's ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Success Rate
Study was conducted in Spain with women who declined standard of care surgery ProSense is approved for the treatment of breast cancer throughout the European Union CAESAREA, Israel , Oct. 2, 2023 /PRN...
Renowned Spanish Radiologist Lucía Graña-López to Present Data Using IceCure Medical's ProSense at European Society of Breast Imaging Scientific Meeting 2023
Growing body of evidence-based data is giving women a minimally invasive alternative to the standard of care lumpectomy Patients throughout the European Union have access to ProSense for the treatment...
IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer
CAESAREA, Israel , Sept. 20, 2023 /PRNewswire/ -- IceCure Medical Ltd.
IceCure Medical to Join Hands-On Cryoablation Session with ProSense and Host Symposium Led by Renowned Doctors at the CIRCE 2023 Annual Congress
ProSense is gaining commercial traction in Europe where it has CE approval for numerous malignant and benign tissue indications. Symposium presenters include Professor Francois Cornelis who used ProSe...
IceCure Medical's ProSense Cryoablation System Receives Regulatory Approval in Brazil
$6.6 million in sales expected in Brazilian market over the next five years per distribution agreement guarantees High level of early interest in ProSense in South America's largest market CAESAREA, I...
IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America
Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, including as U.S. Senior Director of Sales at a global leader in minimally invasive breast diagnostic and therap...
IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium
Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with ProSense IceCure joined its exclusive regional distributor, Terumo...
IceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum
Company awaits FDA's response to its regulatory filing for early-stage low risk breast cancer in patients who are at high risk for surgery Renowned physician, Dr. Robert Ward, to participate on the Co...
IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023
CAESAREA, Israel , Aug. 7, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that d...
Health Canada Approves IceCure Medical's Minimally Invasive ProSense Cryoablation System
Strong interest in ProSense from healthcare providers in Canada strengthens market potential ProSense now approved throughout North America CAESAREA, Israel , July 24, 2023 /PRNewswire/ -- IceCure Med...
IceCure Medical Expands Distribution of ProSense® into Portugal Through Agreement with Medicinália Cormédica: Upfront Systems & Probes Sales
ProSense has CE mark of regulatory approval in the European Union Initial purchase of 2 ProSense Systems plus disposable cryoprobes and introducers CAESAREA, Israel , July 17, 2023 /PRNewswire/ -- Ic...
IceCure Medical to Review Recent Progress at Maxim Group's Virtual Healthcare Conference
IceCure CEO, Eyal Shamir, to present and conduct Q&A on Wednesday, June 21 st at 11:00 AM Eastern Time on Track 2 CAESAREA, Israel , June 13, 2023 /PRNewswire/ -- IceCure Medical LTD. (Nasdaq: ICCM) (...
IceCure's ProSense Installation in India is the First to Offer Cryoablation for the Treatment of Breast Cancer in the Country
Latest system installation in IceCure's global commercial rollout of ProSense CAESAREA, Israel , May 31, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense...
IceCure Medical Reports First Quarter 2023 Financial & Operational Results
Physician Interest and Adoption of ProSense in the U.S. Builds Momentum as ProSense is Featured at Medical Conferences and Educational Courses ProSense was the only Cryoablation System Used in a First...
IceCure to Report First Quarter 2023 Financial & Operational Results on May 22, 2023
CAESAREA, Israel, May 15, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by ...